Literature DB >> 11521162

Release of non-neuronal acetylcholine from the human placenta: difference to neuronal acetylcholine.

I Wessler1, E Roth, S Schwarze, W Weikel, F Bittinger, C J Kirkpatrick, H Kilbinger.   

Abstract

The synthesis and release of non-neuronal acetylcholine, a widely expressed signaling molecule, were investigated in the human placenta. This tissue is free of cholinergic neurons, i.e. a contamination of neuronal acetylcholine can be excluded. The villus showed a choline acetyltransferase (ChAT) activity of 0.65 nmol/mg protein per h and contained 500 nmol acetylcholine/g dry weight. In the absence of cholinesterase inhibitors the release of acetylcholine from isolated villus pieces amounted to 1.3 nmol/g wet weight per 10 min corresponding to a fractional release rate of 0.13% per min. The following substances did not significantly modify the release of acetylcholine: oxotremorine (1 microM), scopolamine (1 microM), (+)-tubocurarine (30 microM), forskolin (30 microM), ouabain (10 microM), 4alpha-phorbol 12,13-didecanoate (1 microM) and tetrodotoxin (1 microM). Removal of extracellular calcium, phorbol 12,13-dibutyrate (1 microM) and colchicine (100 microM) reduced the acetylcholine release between 30% and 50%. High potassium chloride (54 mM and 108 mM) increased the acetylcholine release slightly (by about 30%). A concentration of 10 microM nicotine was ineffective, but 100 microM nicotine enhanced acetylcholine release gradually over a 50-min period without desensitization of the response. The facilitatory effect of nicotine was prevented by 30 microM (+)-tubocurarine. Inhibitors of cholinesterase (physostigmine, neostigmine; 3 microM) facilitated the efflux of acetylcholine about sixfold, and a combination of both (+)-tubocurarine (30 microM) and scopolamine (1 microM) halved the enhancing effect. In conclusion, release mechanisms differ between non-neuronal and neuronal acetylcholine. Facilitatory nicotine receptors are present which are activated by applied nicotine or by blocking cholinesterase. Thus, cholinesterase inhibitors increase assayed acetylcholine by two mechanisms, protection of hydrolysis and stimulation of facilitatory nicotine receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521162     DOI: 10.1007/s002100100445

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  6 in total

1.  Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters.

Authors:  I Wessler; E Roth; C Deutsch; P Brockerhoff; F Bittinger; C J Kirkpatrick; H Kilbinger
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Non-neuronal release of ACh plays a key role in secretory response to luminal propionate in rat colon.

Authors:  Takaji Yajima; Ryo Inoue; Megumi Matsumoto; Masako Yajima
Journal:  J Physiol       Date:  2010-12-06       Impact factor: 5.182

3.  Effects of sex hormones, forskolin, and nicotine on choline acetyltransferase activity in human isolated placenta.

Authors:  Ignaz Wessler; Sören Schwarze; Peter Brockerhoff; Fernando Bittinger; Charles James Kirkpatrick; Heinz Kilbinger
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

4.  Expression of the cholinergic gene locus in the rat placenta.

Authors:  Uwe Pfeil; Reinhard Vollerthun; Wolfgang Kummer; Katrin Susanne Lips
Journal:  Histochem Cell Biol       Date:  2004-07-28       Impact factor: 4.304

Review 5.  Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans.

Authors:  I Wessler; C J Kirkpatrick
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

Review 6.  Acetylcholine and the alpha 7 nicotinic receptor: a potential therapeutic target for the treatment of periodontal disease?

Authors:  Noha Zoheir; David F Lappin; Christopher J Nile
Journal:  Inflamm Res       Date:  2012-07-10       Impact factor: 4.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.